Full Press Release Details
Kamada to Announce Fourth Quarter and Full Year
2022 Financial Results and Host Conference Call on March 15, 2023
Rehovot, Israel, and Hoboken, NJ, March 9,
2023 -- Kamada Ltd. (NASDAQ & TASE: KMDA), a commercial stage global biopharmaceutical company with a portfolio of marketed products
indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that it will release financial
results for the fourth quarter and full year ended December 31, 2022, prior to the open of the U.S. financial markets on Wednesday, March
Kamada management will host an investment community
conference call on Wednesday, March 15, at 8:30am Eastern Time to discuss these results and answer questions. Shareholders and other interested
parties may participate in the conference call by dialing 1-877-407-0792 (from within the U.S.) 1 809-406-247 (from Israel) or 1 201-689-8263
(International). The call will also be webcast live on the Internet at: https://viavid.webcasts.com/starthere.jsp?ei=1582277&tp_key=8121e668e3.
will also be archived for 90 days on the Company's website at www.kamada.com.
Kamada Ltd. (the "Company") is a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated
for rare and serious conditions and a leader in the specialty plasma-derived field, focused on diseases of limited treatment alternatives.
The Company is also advancing an innovative development pipeline targeting areas of significant unmet medical need. The Company's
strategy is focused on driving profitable growth from its significant commercial catalysts as well as its manufacturing and development
expertise in the plasma-derived and biopharmaceutical fields. The Company's commercial products portfolio includes six FDA approved
plasma-derived biopharmaceutical products: CYTOGAM , KEDRAB , WINRHO SDF , VARIZIG , HEPAGAM B and GLASSIA ,
as well as KAMRAB , KAMRHO (D) and two types of equine-based anti-snake venom (ASV) products. The Company distributes its commercial
products portfolio directly, and through strategic partners or third-party distributors in more than 30 countries, including the U.S.,
Canada, Israel, Russia, Argentina, Brazil, India, Australia and other countries in Latin America, Europe, Middle East, and Asia. The Company
leverages its expertise and presence in the Israeli market to distribute, for use in Israel, more than 25 pharmaceutical products that
are supplied by international manufacturers and during recent years added eleven biosimilar products to its Israeli distribution portfolio,
which, subject to the European Medicines Agency (EMA) and the Israeli Ministry of Health approvals, are expected to be launched in Israel
through 2028. The Company owns an FDA registered plasma collection center in Beaumont, Texas, which currently specializes in the collection
of hyper-immune plasma used in the manufacture of KAMRHO (D). In addition to the Company's commercial operation, it invests in research
and development of new product candidates. The Company's leading investigational product is an inhaled AAT for the treatment of
AAT deficiency, for which it is continuing to progress the InnovAATe clinical trial, a randomized, double-blind, placebo-controlled, pivotal
Phase 3 trial. FIMI Opportunity Fund, the leading private equity investor in Israel, is the Company's lead shareholder, beneficially
owning approximately 21% of the outstanding ordinary shares.
Chief Financial Officer
LifeSci Advisors, LLC